October 7, 2025
New Study in Journal of the National Cancer Institute Finds Cologuard PlusTM Provides the Most Life-Years Gained with the Fewest Colonoscopies

September 22, 2025
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test

September 17, 2025
Exact Sciences Launches the OncodetectTM Molecular Residual Disease Test

September 17, 2025
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening

September 17, 2025
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard PlusTM Test Cologuard PlusTM Available In-Network August 2025

September 17, 2025
Cologuard Included in American Cancer Society Colorectal Cancer Prevention and Early Detection Guidelines

September 10, 2025
Exact Sciences Launches CancerguardTM, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

August 6, 2025
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening tests

August 6, 2025
Exact Sciences Announces Second Quarter 2025 Results

July 31, 2025
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard PlusTM Test Cologuard PlusTM Available In-Network August 2025

July 9, 2025
Exact Sciences Announces Medicare Coverage for OncodetectTM Molecular Residual Disease Test in Colorectal Cancer

May 28, 2025
Exact Sciences Announces Expanded Clinical Validation of the OncodetectTM Test and Molecular Residual Disease Innovation Roadmap

May 22, 2025
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

May 12, 2025
Exact Sciences Earns 2025 Great Place To Work® CertificationTM

May 1, 2025
Exact Sciences Announces First-Quarter 2025 Results

April 29, 2025
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

April 22, 2025
Exact Sciences Launches the OncodetectTM Molecular Residual Disease Test

April 14, 2025
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

March 31, 2025
Exact Sciences Launches the CologuardTM Plus Test, Transforming Colorectal Cancer Screening

March 12, 2025
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

February 19, 2025
Exact Sciences Announces Fourth Quarter 2024 Results

February 5, 2025
Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing

January 21, 2025
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium

January 21, 2025
New Evidence Validates Oncodetect’sTM Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients

January 13, 2025
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

December 2, 2024
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening

November 25, 2024
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

November 18, 2024
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community

November 13, 2024
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

November 5, 2024
Exact Sciences Announces Third-Quarter 2024 Results

October 27, 2024
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

October 4, 2024
FDA Approves Exact Sciences’ Cologuard PlusTM Test, Setting A New Benchmark in Non-Invasive Colorectal Cancer Screening

September 16, 2024
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

August 20, 2024
Exact Sciences Announces First Patient Enrolled in its Multi-Cancer Early Detection (MCED) Falcon Registry Real-World Evidence Study

August 15, 2024
New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion

July 31, 2024
Exact Sciences Announces Second-Quarter 2024 Results

July 17, 2024
Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening

May 24, 2024
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

May 22, 2024
Exact Sciences Earns 2024 Great Place To Work® CertificationTM

May 21, 2024
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy

May 8, 2024
Exact Sciences Announces First-Quarter 2024 Results

May 7, 2024
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024

April 15, 2024
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

April 8, 2024
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

April 5, 2024
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-cancer

April 4, 2024
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to inform treatment

March 27, 2024
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner

March 13, 2024
The New England Journal of Medicine Publishes Cologuard PlusTM Test Results from Pivotal BLUE-C Study

March 7, 2024
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to have a game plan against colon cancer

March 1, 2024
EXACT SCIENCES LAUNCHES RISKGUARDTM HEREDITARY CANCER TEST IN THE UNITED STATES

February 21, 2024
Exact Sciences Announces Fourth Quarter 2023 Results

January 7, 2024
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

December 8, 2023
DAK PRESCOTT JOINS RYAN REYNOLDS’ MAXIMUM EFFORT AND THE COLORECTAL CANCER ALLIANCE TO 'LEAD FROM BEHIND'

December 7, 2023
Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

November 30, 2023
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and individualization of therapy for breast cancer patients

November 20, 2023
Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing at ASCO® 2023

November 17, 2023
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

November 1, 2023
Exact Sciences Announces Third-Quarter 2023 Results

October 22, 2023
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly outperforming fecal immunochemical testing (FIT) for cancer and precancer detection

October 21, 2023
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress

October 9, 2023
Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023

September 12, 2023
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

August 30, 2023
Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical TRIALs

August 21, 2023
Not a Wall But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings

August 1, 2023
Exact Sciences Announces Second-Quarter 2023 Results

June 21, 2023
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations

June 20, 2023
Next Generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent specificity, Raising the Bar in Non-invasive Screening

June 1, 2023
EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATIONTM

May 17, 2023
EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

May 9, 2023
Exact Sciences Announces First Quarter 2023 Results

May 9, 2023
Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting

April 12, 2023
EXACT SCIENCES PRESENTS ADVANCEMENTS IN CANCER DETECTION AT AMERICAN ASSOCIATION FOR CANCER RESEARCH® 2023 ANNUAL MEETING

February 21, 2023
Exact Sciences Announces Fourth Quarter 2022 Results

February 7, 2023
Exact Sciences Launches OncoExTraTM Cancer Therapy Selection Test in the U.S.

February 1, 2023
Exact Sciences and PGA Tour Champions Extend Partnership Through 2027

January 8, 2023
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results

January 7, 2023
Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard® Test

September 22, 2022
Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations

July 8, 2022
Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

April 28, 2022
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

March 7, 2022
Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

January 10, 2022
Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

January 10, 2022
Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

December 9, 2021
Exact Sciences Commits $500,000 to Urban League Black Business Hub

December 1, 2021
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

September 14, 2021
Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

May 19, 2021
Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

April 1, 2021
New NCCN Breast Cancer Guidelines Recognize Oncotype DX Breast Recurrence Score® Test

December 11, 2020
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice

December 9, 2020
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

November 2, 2020
Exact Sciences Mourns the Death of Dr. David Ahlquist, a Pioneer in Early Cancer Detection

May 29, 2020
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

May 14, 2020
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

March 15, 2020
Message from Chairman & CEO, Kevin Conroy

December 5, 2019
Dr. David Ahlquist, Co-Inventor of Cologuard, Named a Fellow of the National Academy of Inventors

November 8, 2019
Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

November 8, 2019
Exact Sciences Presents Data on Blood-based Test for Detection of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation

September 24, 2019
PGA Tour Champions and Exact Sciences Announce Five-year Extension of Cologuard Classic

September 23, 2019
Cologuard® Gains FDA Approval for Use in Younger Americans, Ages 45 to 49

September 19, 2019
Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work and Fortune

July 29, 2019
Exact Sciences And Genomic Health To Combine, Creating Leading Global Cancer Diagnostics Company

July 17, 2019
Exact Sciences Designated a Great Place to Work-CertifiedTM Company in 2019

June 26, 2019
Exact Sciences Advances Fight Against Colorectal Cancer with Opening of New Laboratory

May 30, 2018
Exact Sciences Applauds American Cancer Society's Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49

July 25, 2017
Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests

April 4, 2017
CMS includes Cologuard in updated Medicare Advantage Star Ratings

August 15, 2016
CMS Affirms Cologuard® Covered Every Three Years for Medicare Advantage Beneficiaries Without Cost Sharing

June 15, 2016
Exact Sciences' Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations

October 19, 2015
Stool DNA Screening Technology to be Featured at ACG 2015

November 12, 2014
Cologuard® Wins Popular Science Magazine's 2014 "Best of What's New" Award

November 6, 2014
Cologuard Included in American Cancer Society Colorectal Cancer Prevention and Early Detection Guidelines

October 9, 2014
Exact Sciences Announces Final National Coverage Determination for Cologuard®

August 12, 2014
FDA Approves Exact Sciences’ Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test

March 28, 2014
Exact Sciences Announces FDA Advisory Committee Unanimously Recommends Approval of Cologuard

March 19, 2014
Exact Sciences’ DeeP-C Study Results Published in New England Journal of Medicine